by Clinical Neuropsychologist | Wednesday, July 3, 2024 | Dementia
Abstract INTRODUCTION Cerebral blood flow (CBF) is reduced in cognitively impaired (CI) Alzheimer’s disease (AD) patients. We checked the sensitivity of time-encoded arterial spin labeling (te-ASL) in measuring CBF alterations in individuals with positive AD...
by Clinical Neuropsychologist | Wednesday, July 3, 2024 | Dementia
Abstract INTRODUCTION Mild cognitive impairment (MCI) is a prodromal stage of dementia. Understanding the mechanistic changes from healthy aging to MCI is critical for comprehending disease progression and enabling preventative intervention. METHODS Patients with MCI...
by Clinical Neuropsychologist | Wednesday, July 3, 2024 | Dementia
Abstract INTRODUCTION We examined the burden of neuropsychiatric symptoms (NPSs) in early-onset (EO) and late-onset (LO) Alzheimer’s disease (AD) and adjusted for age effects via the inclusion of cognitively unimpaired (CU) individuals. METHODS Cross-sectional...
by Clinical Neuropsychologist | Wednesday, July 3, 2024 | Dementia
Abstract INTRODUCTION Sodium-glucose cotransporter 2 (SGLT2) inhibitors exhibit potential benefits in reducing dementia risk, yet the optimal beneficiary subgroups remain uncertain. METHODS Individuals with type 2 diabetes (T2D) initiating either SGLT2 inhibitor or...
by Clinical Neuropsychologist | Wednesday, July 3, 2024 | Dementia
Abstract INTRODUCTION Despite a two-fold risk, individuals of African ancestry have been underrepresented in Alzheimer’s disease (AD) genomics efforts. METHODS Genome-wide association studies (GWAS) of 2,903 AD cases and 6,265 controls of African ancestry....
